Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
Lu Zhao1,2, Qingyun Mei1,2, Yongchao Yu1,2
1Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Abstract:
Great progress has been made in the treatment of driver gene-positive Non- Small Cell Lung Cancer (NSCLC) in recent years. RET fusion was seen in 0.7% to 2% of NSCLC and was associated with younger age and never-smoker status. The pralsetinib and selpercatinib for RET fusion NSCLC was recommended by the 2021 NSCLC treatment guidelines. This review outlines the research progress in the treatment of RET fusion NSCLC, identifies current challenges and describes proposals for improving the outlook for these patients.
Insights
Recent advancements offer new treatments for RET fusion Non-Small Cell Lung Cancer (NSCLC). Targeted therapies like pralsetinib and selpercatinib are now recommended, improving outcomes for this specific patient group.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Non-Small Cell Lung Cancer (NSCLC) treatment has advanced, particularly for driver gene-positive cases.
- RET fusion, found in 0.7-2% of NSCLC, is linked to younger, never-smoker patients.
- Recent guidelines recommend targeted therapies for RET fusion NSCLC.
Purpose of the Study:
- To review research progress in treating RET fusion NSCLC.
- To identify current challenges in managing this NSCLC subtype.
- To propose strategies for improving patient outcomes.
Main Methods:
- Literature review of recent studies on RET fusion NSCLC treatment.
- Analysis of treatment guidelines and clinical trial data.
- Synthesis of findings to address challenges and propose future directions.
Main Results:
- Significant progress in targeted therapies for RET fusion NSCLC.
- Pralsetinib and selpercatinib are recommended by 2021 guidelines.
- Understanding of RET fusion's association with specific patient demographics.
Conclusions:
- Targeted therapies have transformed RET fusion NSCLC treatment.
- Addressing current challenges is crucial for further improving patient survival.
- Future research should focus on optimizing treatment strategies and overcoming resistance mechanisms.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...